CFRXQ

0.0001--
RJ

Roger James Pomerantz

Chairman

Dr. Roger James Pomerantz, M. D., F. A.C. P., serves as Director at X-Vax Technology, Inc. He serves as an Independent Vice Chairman of the Board of Enlivex Therapeutics Ltd. since May 2022. He is Independent Chairman of the Board at Indaptus Therapeutics, Inc. since July 2021 and Director since 2021. He serves as the Director at VerImmune Inc. He was Independent Chairman at Intec Pharma Ltd. He has been Chairman of ContraFect Corporation since April 2, 2019 and serves as its President and Chief Executive Officer since April 2, 2019 until November 15, 2023. Dr. Pomerantz serves as Chairman of the Board at Silicon Therapeutics LLC, since July 2019. He serves as Chairman of CollPlant Biotechnologies Ltd. since February 10, 2020. He has been Chairman of the Board at Viracta Therapeutics, Inc. (formerly known as Sunesis Pharmaceuticals, Inc.) since September 2020 and has been its Independent Director since June 2020. He served as Venture Partner of Flagship Pioneering (formerly known as Flagship Ventures) from 2014 to 2019. He joined the Flagship Pioneering in 14th July 2014. He served as a senior Partner at the Flagship Pioneering. Dr. Pomerantz focused on providing strategic counsel and support to the Flagship team as well as to portfolio companies through Board and advisory roles. Dr. Pomerantz serves on the Board of Directors of X-Vax Inc. He also served as CEO of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz had been the Chief Executive Officer and President of Seres Therapeutics, Inc. (formerly, Seres Health, Inc.) since June 2014 until January 15, 2018. He was the Chairman of Scientific Advisory Board at Aridis Pharmaceuticals, Inc. He served as the President of Tibotec-Virco NV since September 2005. He serves as the President of Janssen R&D Ireland. Dr. Pomerantz served as Senior Vice President of Johnson and Johnson, Inc. From January 2011 to September 2013, he served as Senior Vice President and Worldwide Head of Licensing and Acquisitions at Merck & Co., Inc., where he oversaw licensing and acquisitions for Merck Research Laboratories, the research and development division of Merck. He was Global Franchise Head of Infectious Diseases and Senior Vice President at Merck Research Laboratories, where he oversaw pharmaceutical development and discovery of antibiotics, antivirals, antifungals and antiparasitic agents. Dr. Pomerantz has extensive academic and clinical experience, as well as knowledge in the pharmaceutical industry. Prior to joining Merck, he served as the Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He was responsible for anti-infective agents worldwide. He joined Johnson & Johnson in August 2005 as the President of Tibotec Pharmaceuticals, Inc. (now Janssen Therapeutics). He served as the President of Janssen Infectious Diseases-Diagnostics BVBA since September 1, 2005. He served as Chief of Infectious Diseases and the Founding Director and Chairman of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He was a Professor of Medicine, Biochemistry and Molecular Pharmacology at Thomas Jefferson University and Medical School. He has been Director of Intec Pharma Ltd. since March 22, 2018. He was Vice Chairman of ContraFect Corporation from May 2014 to April 2, 2019 and has been its Director since April 2014. He has been the Chair of Scientific Advisory Board at Novira Therapeutics, Inc. since August 26, 2014. He served as a Director of Rubius Therapeutics, Inc. from December 2014 until March 19, 2018. He serves as a Member of Scientific Advisory Board at BSI Healthcapital SA. He served as a Director of Evelo Therapeutics, Inc. until May 31, 2016 and at Evelo Biosciences, Inc. until May 31, 2016. He had been the Chairman of the Board of Seres Therapeutics, Inc. since November 21, 2013 until December, 2019 and serves as its Advisor. He has developed twelve small and large molecule drugs approved world-wide in critical human diseases, including HIV, HCV, CMV, C. difficile and multi-drug resistant tuberculosis. He is Board Certified in both Internal Medicine and Infectious Diseases. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the WhiteHead Institute at M. I.T., in the laboratory of Nobel Laureate, Dr. David Baltimore. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the WhiteHead Institute of the Massachusetts Institute of Technology (MIT). He completed his Internal Medicine internship and residency training and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (MGH) and served as the Chief Medical Resident at MGH. He served as Chief Resident at Massachusetts General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. is an internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection. He received his B. A. in Biochemistry from the Johns Hopkins University (1975-1978) and his M. D. from the Johns Hopkins School of Medicine (1979-1982). He received Post-Graduate Training from the Massachusetts General Hospital, Harvard Medical School and M. I.T.

Positions